Healthy Returns: Trump’s FDA pick Makary may be a relief for biotech and pharma, analysts say
Trump's FDA pick, Marty Makary, appears to be quelling fears about a major disruption to biotech and pharma. Neuralink approved for new studies, company says.
Trump's FDA pick, Marty Makary, appears to be quelling fears about a major disruption to biotech and pharma. Neuralink approved for new studies, company says.
